{"id":"W4405043434","doi":"10.1182/blood-2024-200701","title":"Fixed-Duration Acalabrutinib Plus Venetoclax with or without Obinutuzumab Versus Chemoimmunotherapy for First-Line Treatment of Chronic Lymphocytic Leukemia: Interim Analysis of the Multicenter, Open-Label, Randomized, Phase 3 AMPLIFY Trial","year":2024,"lang":"en","type":"article","venue":"Blood","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":15,"is_retracted":false,"has_abstract":true,"ca_institutions":"AstraZeneca (Canada); University of Calgary; Foothills Medical Centre; University of Ottawa","funders":"","keywords":"Obinutuzumab; Venetoclax; Chemoimmunotherapy; Medicine; Internal medicine; Oncology; Chronic lymphocytic leukemia; Interim analysis; Fludarabine; Leukemia; Randomized controlled trial; Cyclophosphamide; Chemotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.004209649,0.001979619,0.002496974,0.0004535963,0.0003880874,0.001432541,0.001153209,0.001465843,0.006256714],"category_scores_gemma":[0.002679544,0.0006307957,0.003022407,0.0003692574,0.001132395,0.001437969,0.0005756692,0.003782377,0.001005322],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008977089,"about_ca_system_score_gemma":0.001281107,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007263353,"about_ca_topic_score_gemma":0.001791135,"domain_scores_codex":[0.9987755,0.0007699525,0.00005074994,0.0001535293,0.00006783635,0.000182359],"domain_scores_gemma":[0.9980019,0.0006626581,0.0005452369,0.0002063123,0.00008949971,0.0004944475],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9859865,0.003217421,0.0005743704,0.0001644977,0.0008448666,0.00001433484,0.00002859042,0.0004649923,0.0008912241,0.00009119352,0.0005659997,0.007155981],"study_design_scores_gemma":[0.9095356,0.08533754,0.001886366,0.00003250009,0.0009944362,0.0000360036,0.00002207679,0.0008067454,0.0004511181,0.0002703663,0.000612697,0.00001449045],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9862272,0.003847588,0.0009053503,0.0007106539,0.0004544811,0.002922731,0.001677674,0.0001851147,0.003069126],"genre_scores_gemma":[0.9888514,0.001356523,0.001664603,0.0009074118,0.0004234878,0.002691345,0.001677858,0.00003450263,0.002392886],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006256714,"threshold_uncertainty_score":0.02226305,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.0857842112642104,"score_gpt":0.4075480686450218,"score_spread":0.3217638573808114,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}